ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Merck and Akeso side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

MerckAkeso
studies on the registry2,455166
open to participants now14667
phase 3 studies under way11225
reach primary completion within a year5929
programswith a study of their own in two years8417

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseMerckAkeso
Phase 1

Merck: 27 of its 84 programs at phase 1

  1. MK4646phase 1
  2. F-2phase 1
  3. MK-7602phase 1
  4. V118Cphase 1
  5. MK-4716phase 1

and 22 more — sign in to see them all

32%

Akeso: 6 of its 17 programs at phase 1

  1. AK 135phase 1
  2. AK150phase 1
  3. AK152phase 1
  4. AK154phase 1
  5. AK157D1 for injectionphase 1

and 1 more — sign in to see them all

35%
Phase 223%

Akeso: 5 of its 17 programs at phase 2

  1. AK139phase 2
  2. AK138D1phase 2
  3. AK146D1phase 2
  4. Anti-PD-1/LAG-3 Bispecific Antibody AK129phase 2
  5. tinengotinibphase 2
29%
Phase 3

Merck: 35 of its 84 programs at phase 3

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. tulisokibartphase 3
  4. ifinatamab deruxtecanphase 3
  5. intismeran autogenephase 3

and 30 more — sign in to see them all

42%

Akeso: 6 of its 17 programs at phase 3

  1. ivonescimabphase 3
  2. cadonilimabphase 3
  3. ligufalimabphase 3
  4. AK120phase 3
  5. ebronucimabphase 3

and 1 more — sign in to see them all

35%
Approved, new studies

Merck: 3 of its 84 programs at approved, new studies

  1. pembrolizumabapproved, new study
  2. sotaterceptapproved, new study
  3. Metforminapproved, new study
4%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Merck25 readouts · 6 phase 3·

Merck, Dec ’26: 3 programs whose next study reaches primary completion

  1. enlicitide chloridephase 3 · Dec 14 · NCT07776665
  2. F-2phase 1 · Dec 15 · NCT07748351
  3. efitazanamivir alfaphase 3 · Dec 31 · NCT07300085

Merck, Jan ’27: 4 programs whose next study reaches primary completion, 3 in phase 3

  1. remigromigphase 3 · Jan 11 · NCT06957080
  2. Human Papillomavirus Recombinant Vaccine nonavalentphase 3 · Jan 15 · NCT04199689
  3. alimatravirphase 3 · Jan 19 · NCT07600775
  4. pembrolizumabapproved, new study · Jan 31 · NCT04241185

Merck, Feb ’27: 4 programs whose next study reaches primary completion

  1. nemtabrutinibphase 3 · Feb 1 · NCT07734610
  2. MK-6916phase 2 · Feb 9 · NCT07862621
  3. tulisokibartphase 3 · Feb 17 · NCT07486960
  4. belzutifanphase 3 · Feb 26 · NCT03634540

Merck, Mar ’27: 1 program whose next study reaches primary completion

  1. ensifentrinephase 3 · Mar 1 · NCT05270525

Merck, Apr ’27: 3 programs whose next study reaches primary completion

  1. MK-7602phase 1 · Apr 5 · NCT07919028
  2. pyronaridinephase 1 · Apr 5 · NCT07919028
  3. intismeran autogenephase 3 · Apr 23 · NCT06305767

Merck, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sacituzumab tirumotecanphase 3 · May 10 · NCT06074588

Merck, Jun ’27: 2 programs whose next study reaches primary completion

  1. ifinatamab deruxtecanphase 3 · Jun 12 · NCT07405151
  2. ulonivirinephase 3 · Jun 29 · NCT05093972

Merck, Jul ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. V118Ephase 1 · Jul 6 · NCT07168915
  2. bomedemstatphase 3 · Jul 14 · NCT06079879
  3. Anti-nectin-4 Antibody-drug Conjugate MK-3120phase 2 · Jul 30 · NCT07222488

Merck, Aug ’27: 1 program whose next study reaches primary completion

  1. islatravirphase 3 · Aug 10 · NCT06891066

Merck, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zilovertamab vedotinphase 3 · Sep 24 · NCT05139017

Merck, Oct ’27: 2 programs whose next study reaches primary completion

  1. HRS-5346phase 2 · Oct 12 · NCT07614984
  2. MK-8690phase 2 · Oct 19 · NCT07895524
Akeso8 readouts · 1 phase 3

Akeso, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. cadonilimabphase 3 · Nov 0 · NCT06341335

Akeso, Dec ’26: 4 programs whose next study reaches primary completion

  1. Anti-PD-1/LAG-3 Bispecific Antibody AK129phase 2 · Dec 0 · NCT06943820
  2. ivonescimabphase 3 · Dec 0 · NCT05689853
  3. AK139phase 2 · Dec 27 · NCT07436221
  4. ligufalimabphase 3 · Dec 30 · NCT05227664
····

Akeso, May ’27: 1 program whose next study reaches primary completion

  1. tinengotinibphase 2 · May 10 · NCT07052253

Akeso, Jun ’27: 1 program whose next study reaches primary completion

  1. AK152phase 1 · Jun 0 · NCT07301502
··

Akeso, Sep ’27: 1 program whose next study reaches primary completion

  1. AK146D1phase 2 · Sep 1 · NCT07591090
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 24, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Merck

New programs 7

  • V951Aphase 1 · first study · Nov 10
  • pyronaridinephase 1 · first study · Oct 30 · Malaria, Falciparum
  • MK-2750phase 2 · first study · Oct 9 · Neoplasms
  • MK-6255phase 1 · first study · Oct 6 · Ovarian Neoplasms
  • V175phase 1 · first study · Sep 28
  • V175Aphase 1 · first study · Sep 28
  • Merck: new programs in 90 days

    1. V951Aphase 1 · first study · Nov 10
    2. pyronaridinephase 1 · first study · Oct 30
    3. MK-2750phase 2 · first study · Oct 9
    4. MK-6255phase 1 · first study · Oct 6
    5. V175phase 1 · first study · Sep 28

    and 2 more — sign in to see them all

Reached a new phase 2

  • gocatamigphase 3 · Oct 26 · Small Cell Lung Carcinoma
  • MK-6916phase 2 · Oct 2 · Renal Insufficiency

Study stopped 4

Primary completion later 6

Akeso

New programs 2

Reached a new phase 0

None

Study stopped 1

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 21 in all. A program counts in each condition its studies name most.

ConditionMerckAkeso
Neoplasmsboth · compare here

Merck in Neoplasms: 14 programs

  1. belzutifanphase 3
  2. ifinatamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. calderasibphase 3
  5. opevesostatphase 3

and 9 more — sign in to see them all

Their studies: Merck’s studies of Neoplasms in search

Akeso in Neoplasms: 1 program

  1. ligufalimabphase 3

Their studies: Akeso’s studies of Neoplasms in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Merck in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. sacituzumab tirumotecanphase 3
  2. ifinatamab deruxtecanphase 3
  3. intismeran autogenephase 3
  4. patritumab deruxtecanphase 3
  5. calderasibphase 3

and 5 more — sign in to see them all

Their studies: Merck’s studies of Carcinoma, Non-Small-Cell Lung in search

Akeso in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. ivonescimabphase 3
  2. cadonilimabphase 3
  3. AK138D1phase 2

Their studies: Akeso’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsboth · compare here

Merck in Breast Neoplasms: 3 programs

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. patritumab deruxtecanphase 3

Their studies: Merck’s studies of Breast Neoplasms in search

Akeso in Breast Neoplasms: 3 programs

  1. AK138D1phase 2
  2. AK146D1phase 2
  3. tinengotinibphase 2

Their studies: Akeso’s studies of Breast Neoplasms in search

Triple Negative Breast Neoplasmsboth · compare here

Merck in Triple Negative Breast Neoplasms: 3 programs

  1. sacituzumab tirumotecanphase 3
  2. zilovertamab vedotinphase 3
  3. boserolimabphase 2

Their studies: Merck’s studies of Triple Negative Breast Neoplasms in search

Akeso in Triple Negative Breast Neoplasms: 3 programs

  1. ivonescimabphase 3
  2. ligufalimabphase 3
  3. tinengotinibphase 2

Their studies: Akeso’s studies of Triple Negative Breast Neoplasms in search

Carcinoma, Renal Cellboth · compare here

Merck in Carcinoma, Renal Cell: 4 programs

  1. belzutifanphase 3
  2. intismeran autogenephase 3
  3. raludotatug deruxtecanphase 3
  4. zanzalintinibphase 3

Their studies: Merck’s studies of Carcinoma, Renal Cell in search

Akeso in Carcinoma, Renal Cell: 1 program

  1. cadonilimabphase 3

Their studies: Akeso’s studies of Carcinoma, Renal Cell in search

Ovarian Neoplasmsboth · compare here

Akeso in Ovarian Neoplasms: 1 program

  1. ivonescimabphase 3

Their studies: Akeso’s studies of Ovarian Neoplasms in search

Alzheimer Diseaseboth · compare here

Merck in Alzheimer Disease: 3 programs

  1. MK-2214phase 2
  2. BCG Vaccinephase 2
  3. MK-1167phase 2

Their studies: Merck’s studies of Alzheimer Disease in search

Akeso in Alzheimer Disease: 1 program

  1. AK152phase 1

Their studies: Akeso’s studies of Alzheimer Disease in search

Hypercholesterolemiaboth · compare here

Merck in Hypercholesterolemia: 3 programs

  1. enlicitide decanoatephase 3
  2. enlicitide chloridephase 3
  3. rosuvastatinphase 3

Their studies: Merck’s studies of Hypercholesterolemia in search

Akeso in Hypercholesterolemia: 1 program

  1. ebronucimabphase 3

Their studies: Akeso’s studies of Hypercholesterolemia in search

Small Cell Lung Carcinomaboth · compare here

Merck in Small Cell Lung Carcinoma: 3 programs

  1. ifinatamab deruxtecanphase 3
  2. gocatamigphase 3
  3. boserolimabphase 2

Their studies: Merck’s studies of Small Cell Lung Carcinoma in search

Akeso in Small Cell Lung Carcinoma: 1 program

  1. ivonescimabphase 3

Their studies: Akeso’s studies of Small Cell Lung Carcinoma in search

Carcinoma, Transitional Cellboth · compare here

Akeso in Carcinoma, Transitional Cell: 1 program

  1. AK146D1phase 2

Their studies: Akeso’s studies of Carcinoma, Transitional Cell in search

Colorectal Neoplasmsboth · compare here

Merck in Colorectal Neoplasms: 2 programs

  1. zanzalintinibphase 3
  2. Cetuximabphase 3

Their studies: Merck’s studies of Colorectal Neoplasms in search

Akeso in Colorectal Neoplasms: 1 program

  1. ivonescimabphase 3

Their studies: Akeso’s studies of Colorectal Neoplasms in search

Dermatitis, Atopicboth · compare here

Merck in Dermatitis, Atopic: 1 program

  1. MK-6194phase 2

Their studies: Merck’s studies of Dermatitis, Atopic in search

Akeso in Dermatitis, Atopic: 2 programs

  1. AK120phase 3
  2. AK139phase 2

Their studies: Akeso’s studies of Dermatitis, Atopic in search

Hyperlipidemiasboth · compare here

Merck in Hyperlipidemias: 2 programs

  1. enlicitide chloridephase 3
  2. rosuvastatinphase 3

Their studies: Merck’s studies of Hyperlipidemias in search

Akeso in Hyperlipidemias: 1 program

  1. ebronucimabphase 3

Their studies: Akeso’s studies of Hyperlipidemias in search

Leukemia, Myeloid, Acuteboth · compare here

Merck in Leukemia, Myeloid, Acute: 2 programs

  1. bomedemstatphase 3
  2. pyronaridinephase 1

Their studies: Merck’s studies of Leukemia, Myeloid, Acute in search

Akeso in Leukemia, Myeloid, Acute: 1 program

  1. ligufalimabphase 3

Their studies: Akeso’s studies of Leukemia, Myeloid, Acute in search

Squamous Cell Carcinoma of Head and Neckboth · compare here

Merck in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. Cetuximabphase 3
  2. pembrolizumabapproved, new study

Their studies: Merck’s studies of Squamous Cell Carcinoma of Head and Neck in search

Akeso in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. Anti-PD-1/LAG-3 Bispecific Antibody AK129phase 2

Their studies: Akeso’s studies of Squamous Cell Carcinoma of Head and Neck in search

Asthmaboth · compare here

Merck in Asthma: 1 program

  1. ensifentrinephase 3

Their studies: Merck’s studies of Asthma in search

Akeso in Asthma: 1 program

  1. AK120phase 3

Their studies: Akeso’s studies of Asthma in search

Hyperlipoproteinemia Type IIboth · compare here

Merck in Hyperlipoproteinemia Type II: 1 program

  1. enlicitide decanoatephase 3

Their studies: Merck’s studies of Hyperlipoproteinemia Type II in search

Akeso in Hyperlipoproteinemia Type II: 1 program

  1. ebronucimabphase 3

Their studies: Akeso’s studies of Hyperlipoproteinemia Type II in search

Prostatic Neoplasmsboth · compare here

Merck in Prostatic Neoplasms: 1 program

  1. opevesostatphase 3

Their studies: Merck’s studies of Prostatic Neoplasms in search

Akeso in Prostatic Neoplasms: 1 program

  1. tinengotinibphase 2

Their studies: Akeso’s studies of Prostatic Neoplasms in search

Psoriasisboth · compare here

Merck in Psoriasis: 1 program

  1. MK-8644phase 1

Their studies: Merck’s studies of Psoriasis in search

Akeso in Psoriasis: 1 program

  1. gumokimabphase 3

Their studies: Akeso’s studies of Psoriasis in search

Stomach Neoplasmsboth · compare here

Merck in Stomach Neoplasms: 1 program

  1. pembrolizumabapproved, new study

Their studies: Merck’s studies of Stomach Neoplasms in search

Akeso in Stomach Neoplasms: 1 program

  1. cadonilimabphase 3

Their studies: Akeso’s studies of Stomach Neoplasms in search

Uterine Cervical Neoplasmsboth · compare here

Akeso in Uterine Cervical Neoplasms: 1 program

  1. cadonilimabphase 3

Their studies: Akeso’s studies of Uterine Cervical Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Merck 40 of 84 · Akeso 4 of 17 programs (17 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.